Galectin Therapeutics 8K Regulation FD Disclosure | GALT 6 Feb 08

P R O -

P H A R M A C E U T I C A L S , I N C .

Amex: P R W

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E®

Exhibit 99.1

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

Forward Looking Statements

Any

statements

this

presentation

about

future

expectations,

plans

and

prospects

for

the

Company,

including

statements

containing

the

words

"believes,"

"anticipates,"

"plans,"

"expects

and

similar

expressions,

constitute

forward

looking

statements,

which

are

subject

the

safe

harbor

for

such

statements

the

Private

Securities

Litigation

Reform

Act

1995.

Future

events

could

cause

actual

results

differ

materially

from

those

indicated

such

statements.

Reference

made

the

factors

discussed

the

"Plan

Operations"

and

"Risk

Factors"

sections

the

Company's

most

recent

quarterly

annual

report

filed

with

the

Securities

and

Exchange

Commission.

The

forward-

looking

statements

herein

represent

the

Company's

views

the

date

this

presentation

and

should

not

relied

upon

represent

the

Company's

views

subsequent

date.

While

the

Company

anticipates

that

subsequent

events

may

cause

the

Company's

views

change,

the

Company

disclaims

any

obligation

update

such

forward-

looking statements.

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

Mission

Develop proprietary carbohydrate

compounds with the potential to

significantly improve treatments for

cancer, liver, inflammatory and microbial

diseases. This improvement is based on

identifying and exploiting the unique

biological specificity carbohydrates have

for disease receptors.

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

Summary

•

Unique Technology

–

Multiple drug platforms

•

Positive pre-clinical and clinical trial

results

•

Regulatory Strategy

•

Business Opportunities

–

Multi-billion dollar markets

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

Technology

•

Oncology

•

Fibrosis

•

Other opportunities

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

Overview -

Technology

•

Unique Technology

–

Drug design using carbohydrates

–

Five

patents

issued

and

eleven

pending

–

Highly specific recognition mechanisms

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

Strong Intellectual Property Position

Carbohydrate Polymers

•

Composition of matter and field of use

patents (5)

–

U.S. Pat 6,642,205

(11/04/03) –

Methods and

Compositions for Reducing side effects in

Chemotherapeutic Treatments

–

U.S. Pat 6,645,946

(11/11/03) & U.S. Pat 6,982,255

(01/03/06) & U.S. Pat 6,914,055

(07/05/06) –

Delivery of

a Therapeutic Agent in a Formulation for Reduced

Toxicity

–

U.S. Pat 7,012,068

(03/14/06) –

Co-administration of a

Polysaccharide with a Chemotherapeutic agent for the

Treatment of Cancer

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

Composition of Matter and Methods of Delivery

Key Claims

•

Methods and compositions for reducing toxicity of an

existing chemotherapeutic drug by co-administering a

polysaccharide

•

UNIVERSAL CARBOHYDRATE LINKER

TECHNOLOGY (UCLT™) enhances the delivery of

chemotherapy drugs to tumor cells

•

Covalently binds one carbohydrate compound to a

chemotherapy drug

•

Utilizes carbohydrate specific receptors found on

cancer cells to target delivery

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

Strong Intellectual Property Position

11 new patent applications filed

•

2 -

enhanced treatment of cancer

including reduced side effects

•

3 -

delivery of anti-cancer drugs

•

1 -

reducing side effects of

chemotherapeutic treatments

•

1 -

formulation for anti-fibrotic therapies

•

2 –

carbohydrate derived statins

•

1 -

composition of anti-microbial agent

•

compositions and methods to inhibit

restenosis

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

LEAD COMPOUND

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

��

Amex: P R W

Targeting Lectins

•

Lectins are proteins that tightly bind certain

carbohydrates

•

Galectins are a type of lectin that specifically bind

galactose molecules

•

Galectin receptors are predominately on cancer

cells

•

Galectins have been shown to affect cell

development, differentiation, apoptosis and tumor

metastasis

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

•

Proprietary polysaccharide that targets

Galectin receptors on cancer cells

•

Increases efficacy and decreases toxicity of

chemotherapeutic agents

•

Currently in Phase ll trials

DAVANAT

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

•

DAVANAT

selectively binds to lectin

receptors on cancer cells

•

Once bound, the polymer releases its

payload into the cancer cell

Oncology Platform: CARBOSOME™

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

Second

Platform:

Universal Carbohydrate Linker Technology

•

New chemical entity that contains a carbohydrate backbone

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

CLINICAL TRIAL RESULTS

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

Pre-Clinical Results

DAVANAT®

mixed with Avastin®

and with 5-FU

showed best results –

SLOWEST TUMOR GROWTH

Tumor Weight Gain in Mice Implanted with COLO 205, Human

Colon Tumor, Treated with DAVANAT® in Combination with 5-FU

& Bevacizumab (Avastin®)

0.0

10.0

20.0

30.0

40.0

50.0

60.0

70.0

80.0

90.0

100.0

Southern Research Institute (Dose: I.V., Q4D x 4, of 5-FU 50 mg/kg; DAVANAT®: 120 mg/kg;

AVASTIN: 20-80 mg/kg)

No Treatment

FU / AV

FU-DAV / AV

FU-DAV / AV-DAV

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

Pre-Clinical Results

DAVANAT®

mixed with Avastin and with 5-FU showed

best results –

Mice Show Healthy Weight Gain

Total Weight Gain of Mice Implanted with COLO 205, Human Colon

Tumor, Treated with DAVANAT® in Combination with 5-FU &

Bevacizumab (Avastin®)

-8.0

-4.0

0.0

4.0

8.0

Southern Research Institute (Dose: I.V., Q4D x 4, of 5-FU 50 mg/kg; DAVANAT®: 120 mg/kg; AVASTIN:

20-80 mg/kg)

No Treatment

FU / AV

FU-DAV / AV

FU-DAV / AV-DAV

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

Pre-Clinical Results

DAVANAT®

mixed with Avastin and with 5-FU showed best

results –

Clinical Benefit Index = Lowest Toxicity and Best Efficacy

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

AUC

Hematocrit

Hemoglobin

Red blood cells

White blood cells

Platelets

Clinical Trial Results

DAVANAT®

mixed with 5-FU eliminated the

expected drop in blood levels from chemotherapy

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

Clinical Trial Summary

Results

•

patients

dosed

with

DAVANAT

/5-FU

Phase

l/ll,

Line

three

and

four

clinical

trials

•

Stabilized

43%

end

stage

patients

with

measurable

disease:

2-13 months

•

Maximum

Tolerated

Dose/Dose

Limiting

Toxicity

not

reached

•

DAVANAT

allowed

increased

5-FU

exposure

with

toxicity

increase

Ongoing

•

Dosing

biliary

and

colorectal

cancer

patients

Phase

ll,

line

one

trials:

–

Colorectal

patients

dosed)

–

PR;

stabilized

months

–

43%

Objective

Response

(more

than

30%

shrinkage)

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

Beyond Oncology

-New Platforms-

•

Use Proprietary IP to Design New Drugs

•

Fibrosis –

Multiple Indications

•

Anti-Microbial

•

Synthetic Statins (Cholesterol)

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

FIBROSIS

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

Fibrosis -

Background

•

Worldwide, 170 million people are infected with chronic hepatitis C

•

10-40% of patients respond to current therapies (notably, removal

of cause)

–

There are no effective therapeutic options

–

1.4 million deaths per year attributed to chronic liver disease

–

In the U.S., liver disease is a top 10 disease-related cause of

death

•

Liver fibrosis is an outcome of persistent hepatic inflammation

•

World wide market in excess of $4 billion

•

Research collaboration with Dr. Scott Friedman, Director Liver

Diseases, Mt. Sinai School of Medicine & President, American

Association for the Study of Liver Diseases

•

PRO-GR

300,

first

class,

carbohydrate

compound

has

shown

pre-clinical

models

not

only

arrest

disease

progression

but

also

reverse

disease

progression

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

Reduces

the

production

Collagen

central

fibrogenesis

diseases

and

the

scarring

organs.

Reduces Expression of Matrix

Metalloproteinase -2 (MMP-2)

MMP-2 has been correlated to the

severity

fibrosis

hepatitis

Reduces Expression of TGFBR1

TGFBR1 plays a key role in initiating the

cascade of events causes the formation

fibrosis

scar

tissue

Mechanism of Action -

Effect

on Fibrotic Markers In-vitro

Addition of PRO-GR 300 to fibrotic liver cells:

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

Reversal of Fibrosis with

PRO–GR 300 after 4 weeks

of treatment

Liver Fibrosis, induced by injection

of chemical toxin for 8 weeks

Rat

Fibrosis

Model

Proof of Concept

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

Other Fibrosis Applications

•

The same receptors influence many types of Fibrosis

•

Therefore PRO-GR 300 may be effective in different types of

Fibrosis

•

Chemical toxicity, microbial infection & physical injury cause

hepatic, renal, cardiac and pulmonary fibrosis

•

Kidney Fibrosis

–

12 million people suffer from kidney fibrosis in the U.S.

–

Research collaboration with Brigham and Women's

Hospital -

affiliate of Harvard Medical School

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

Regulatory Strategy

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

Regulatory Strategy

•

Submit final report for completed Phase II end stage patient trial

•

Continue Phase II trials underway

•

Drug Master File (Mfg data) to FDA

•

Initiate IND for non-intravenous indications, e.g., Melanoma

•

File for Approval to Market DAVANAT®

as Excipient with 5-FU

•

Animal studies needed to add DAVANAT®

to other chemos

•

Regional partnership approach for DAVANAT®

•

Partner for Phase III trials

Oncology

Fibrosis

•

Animal studies needed to extend proof of concept

•

Accelerate liver & kidney pre-clinical trials

•

File IND for human trials

•

Seek partnership

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

Product Development Pipeline Jan 2008

PRODUCT

INDICATION

DISCOVERY

PRE-CLINICAL

PHASE 1

PHASE 2

DAVANAT

/ 5-FU line I

DAVANAT

/ 5-FU/LV/

AVASTIN

line I

DAVANAT

/ 5-FU line IV

PRO-GR 300

Biliary Cancer

Ongoing

Colorectal Cancer

Ongoing

All Solid Tumors

Completed

Liver Disease

Microbial Disease

PHASE 3

DAVANAT

/ 5-FU line IV

Colorectal Cancer

Completed

PRO-NAC 050

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

2008 Milestones

•

Submit Drug Master File (DMF) -

First Quarter

•

File Investigative New Drug (IND) Application: Triggers

FDA Review of DMF -

Second Quarter

•

DMF approval projected –

Second/Third Quarter

•

License DAVANAT®

in regions outside U.S. –

Third Quarter

•

Submit data needed for approval as excipient to 5-FU –

Fourth Quarter

•

Continue to complete research agreements

•

Actively pursue corporate partnerships

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

Business Opportunities

Several

Multi-billion dollar markets can

be addressed

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

Business Opportunities

•

Oncology

–

Excipient to 5-FU, improve results & reduce side effects

–

Eliminates/reduces need for additional drugs to treat side effects

–

Extend patent life of chemo drugs

–

Only animal studies needed to combine with other chemo

–

New indications -

melanoma

–

Regional licenses

–

Partner with big Pharma to fund trials

•

Avastin®

sales in 2007 $2.9 billion –

Works with 5-FU

–

Low Cost to Produce

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

Business Opportunities

Several Multi-billion dollar markets can be

addressed

•

Fibrosis

–

Accelerate pre-clinical trials based on proven safety of

carbohydrates and DAVANAT®

•

Liver

•

Kidney

–

File IND

–

Start clinical trials ASAP

–

Early partnerships

–

New indications –

lung fibrosis

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

CORPORATE

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

Corporate Summary

•

PRW began operations in 2001

•

Five U.S. patents issued

•

Capital raised: $39.5 million (cumulative)

•

Shares outstanding: 40.4 million (11/01/07)

•

Fully diluted: 52.1 million (11/01/07)

•

Completed Phase l/ll cancer trials, line 3-4

•

Two ongoing Phase ll trials, line 1, biliary & colorectal cancer

•

PRO-GR 300

in pre-clinical trials to treat fibrosis

•

Plan to commercialize technology and products through

corporate partnerships

•

Carbohydrate technology platform enables:

–

New intellectual property

–

Product line extensions

–

Safer and more effective drugs

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

Management Team

•

David Platt, Ph.D., Chairman & Chief Executive Officer

–

Co-founder, co-developer of Glycoscience technology. Founder: SafeScience; developed

anti-angiogenesis drug. U of Michigan, Weizmann Institute, Hebrew U

•

Theodore Zucconi, Ph.D., President

–

35 + years experience in operations management, R&D, problem solving, product

development and strategic planning

•

Anatole Klyosov, Ph.D., D.Sc., Chief Scientist

–

Co-founder, co-developer of Glycoscience technology. National Prize in Science &

Technology (Russia); Visiting Biochemistry Prof at Harvard. Moscow State U

•

Eliezer Zomer, Ph.D., Exec. V.P., Clinical Development & Mfg

–

Former Research Associate at Harvard Medical

•

David Donabedian, Ph.D., MBA, Business Development (Consultant)

–

12 years in life sciences; VP, Bus Dev, Surface Logix; Accenture; Dow Chemical

•

Anthony Squeglia, MBA, Chief Financial Officer

–

25 years in finance, strategic planning, marketing & investor relations

•

Maureen Foley, Chief Operating Officer

–

25 years in biotech, high-tech in operations management

•

Bruce Silver, M.D., Medical Director (Consultant)

–

20 + years in oncology; CRO

P R O

P H A R M A C E U T I C A L S , I N C.

A D V A N C I N G D R U G S T H R O U G H G L Y C O S C I E N C E

Amex: P R W

Summary

•

Proprietary Technology With Multiple Current and

Future Applications

•

Excipient

for Existing Chemotherapy Protocols

•

Reduces or Eliminates Adverse Side Effects and

Lowers Cost of Treatment

•

Proven Effective in Targeting Lectin Receptors

Specific to Cancer Cells

•

New Compound (drug) has Shown Ability to

Reverse Liver Fibrosis

•

Oncology and Fibrosis –

Multi Billion Dollar Markets

Galectin Therapeutics (GALT) 8-KRegulation FD Disclosure